Your browser doesn't support javascript.
loading
Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.
Nakano, Takafumi; Yasumatsu, Ryuji; Hashimoto, Kazuki; Kuga, Ryosuke; Hongo, Takahiro; Yamamoto, Hidetaka; Matsuo, Mioko; Wakasaki, Takahiro; Jiromaru, Rina; Manako, Tomomi; Toh, Satoshi; Masuda, Muneyuki; Yamauchi, Moriyasu; Kuratomi, Yuichiro; Uryu, Hideoki; Nakashima, Torahiko; Tamae, Akihiro; Tanaka, Risa; Taura, Masahiko; Takeuchi, Toranoshin; Yoshida, Takamasa; Nakagawa, Takashi.
Afiliação
  • Nakano T; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Yasumatsu R; Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
  • Hashimoto K; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; yasumatsu.ryuji.847@m.kyushu-u.ac.jp.
  • Kuga R; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Hongo T; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Yamamoto H; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Matsuo M; Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Wakasaki T; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Jiromaru R; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Manako T; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Toh S; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Masuda M; Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
  • Yamauchi M; Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
  • Kuratomi Y; Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
  • Uryu H; Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of Medicine, Saga, Japan.
  • Nakashima T; Division of Otorhinolaryngology and Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
  • Tamae A; Division of Otorhinolaryngology and Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
  • Tanaka R; Department of Otolaryngology, Hamanomachi Hospital, Fukuoka, Japan.
  • Taura M; Department of Internal Medicine, Hamanomachi Hospital, Fukuoka, Japan.
  • Takeuchi T; Department of Otolaryngology Fukuoka University School of Medicine, Fukuoka, Japan.
  • Yoshida T; Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
  • Nakagawa T; Department of Otolaryngology, Sasebo Kyosai Hospital, Sasebo, Japan.
In Vivo ; 36(2): 979-984, 2022.
Article em En | MEDLINE | ID: mdl-35241559
BACKGROUND/AIM: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). PATIENTS AND METHODS: We retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis. RESULTS: EGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases. CONCLUSION: Our results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Salivares / Cisplatino Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: In Vivo Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Salivares / Cisplatino Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: In Vivo Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão